| Year |
Citation |
Score |
| 2020 |
Harrold J, Gisleskog PO, Perez-Ruixo JJ, Delor I, Chow A, Jacqmin P, Melhem M. Prediction of survival benefit of filgrastim in adult and pediatric patients with acute radiation syndrome. Clinical and Translational Science. PMID 32112517 DOI: 10.1111/Cts.12777 |
0.346 |
|
| 2020 |
Belmontes B, Tan H, Zhong W, Chui D, Cook K, O'Brien S, Martin M, Alexander B, Eng J, Harrold J, Aeffner F, Chun M, Bakker A, Balazs M, DeVoss J, et al. Abstract PR12: Assessing in vivo mechanisms regulating the therapeutic activity of bi-specific T-cell engager (BiTE®) molecules in immunocompetent mice expressing a chimeric human/mouse CD3ε receptor Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr12 |
0.327 |
|
| 2018 |
Melhem M, Delor I, Pérez-Ruixo JJ, Harrold J, Chow A, Wu L, Jacqmin P. Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. British Journal of Clinical Pharmacology. PMID 29318653 DOI: 10.1111/Bcp.13504 |
0.343 |
|
| 2016 |
Krzyzanski W, Harrold JM, Wu LS, Perez-Ruixo JJ. A cell-level model of pharmacodynamics-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics. PMID 27612462 DOI: 10.1007/S10928-016-9491-Z |
0.455 |
|
| 2015 |
Krzyzanski W, Perez-Ruixo JJ, Harrold J. Pharmacodynamic model for chemoradiotherapy-induced thrombocytopenia in mice Journal of Pharmacokinetics and Pharmacodynamics. 42: 709-720. PMID 26341875 DOI: 10.1007/S10928-015-9440-2 |
0.382 |
|
| 2015 |
Chudasama VL, Zutshi A, Singh P, Abraham AK, Mager DE, Harrold JM. Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. Journal of Pharmacokinetics and Pharmacodynamics. 42: 1-18. PMID 25559227 DOI: 10.1007/S10928-014-9401-1 |
0.365 |
|
| 2014 |
Harrold JM, Abraham AK. Ubiquity: a framework for physiological/mechanism-based pharmacokinetic/pharmacodynamic model development and deployment. Journal of Pharmacokinetics and Pharmacodynamics. 41: 141-51. PMID 24619141 DOI: 10.1007/S10928-014-9352-6 |
0.329 |
|
| 2014 |
Harrold J, Jacqmin P, Olsson P, Delor I, Morrow PK, Yang B, Chow A, Perez-Ruixo JJ. Translational Modeling to Identify Human Dosing of Filgrastim to Improve Overall Survival (OS) in Acute Radiation Syndrome (ARS) Blood. 124: 690-690. DOI: 10.1182/Blood.V124.21.690.690 |
0.344 |
|
| 2013 |
Harrold JM, Ramanathan M, Mager DE. Network-based approaches in drug discovery and early development. Clinical Pharmacology and Therapeutics. 94: 651-8. PMID 24025802 DOI: 10.1038/Clpt.2013.176 |
0.339 |
|
| 2012 |
Chudasama VL, Schaedeli Stark F, Harrold JM, Tibbitts J, Girish SR, Gupta M, Frey N, Mager DE. Semi-mechanistic population pharmacokinetic model of multivalent trastuzumab emtansine in patients with metastatic breast cancer. Clinical Pharmacology and Therapeutics. 92: 520-7. PMID 22968044 DOI: 10.1038/Clpt.2012.153 |
0.354 |
|
| 2012 |
Vugmeyster Y, Harrold J, Xu X. Absorption, distribution, metabolism, and excretion (ADME) studies of biotherapeutics for autoimmune and inflammatory conditions. Aaps Journal. 14: 714-727. PMID 22798020 DOI: 10.1208/S12248-012-9385-Y |
0.388 |
|
| 2012 |
Harrold JM, Straubinger RM, Mager DE. Combinatorial chemotherapeutic efficacy in non-Hodgkin lymphoma can be predicted by a signaling model of CD20 pharmacodynamics. Cancer Research. 72: 1632-41. PMID 22350416 DOI: 10.1158/0008-5472.Can-11-2432 |
0.381 |
|
| 2010 |
Kagan L, Abraham AK, Harrold JM, Mager DE. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons. Pharmaceutical Research. 27: 920-32. PMID 20232116 DOI: 10.1007/S11095-010-0098-6 |
0.361 |
|
| 2010 |
Zhou R, Mazurchuk RV, Tamburlin JH, Harrold JM, Mager DE, Straubinger RM. Differential pharmacodynamic effects of paclitaxel formulations in an intracranial rat brain tumor model. The Journal of Pharmacology and Experimental Therapeutics. 332: 479-88. PMID 19861574 DOI: 10.1124/Jpet.109.160044 |
0.325 |
|
| 2009 |
Harrold JM, Parker RS. Clinically relevant cancer chemotherapy dose scheduling via mixed-integer optimization Computers & Chemical Engineering. 33: 2042-2054. DOI: 10.1016/J.Compchemeng.2009.06.005 |
0.509 |
|
| 2005 |
Harrold JM, Eiseman JL, Joseph E, Strychor S, Zamboni WC, Parker RS. Control-relevant modeling of the antitumor effects of 9-nitrocamptothecin in SCID mice bearing HT29 human colon xenografts. Journal of Pharmacokinetics and Pharmacodynamics. 32: 65-83. PMID 16205839 DOI: 10.1007/S10928-005-2103-Y |
0.533 |
|
| Show low-probability matches. |